<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04198727</url>
  </required_header>
  <id_info>
    <org_study_id>2017/15</org_study_id>
    <nct_id>NCT04198727</nct_id>
  </id_info>
  <brief_title>Study of the Impact of DPD Activity on the Efficacy of Capecitabine</brief_title>
  <acronym>DPDMAX</acronym>
  <official_title>Study of the Impact of DPD Activity on the Efficacy of Capecitabine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Antoine Lacassagne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cerbaliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Antoine Lacassagne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the Impact of DihydroPyrimidine Dehydrogenase (DPD) activity on the
      efficacy of Capecitabine in patients with metastatic breast cancer. The DPD phenotype before
      the initiation of treatment will be assess and then the patient will be follow up during the
      treatment with Capecitabine up to 24 month.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2020</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an open-label multi-center prospective cohort study to compare the response of patients with high phenotype to patients with normal phenotype. The analyzes performed will focus on clinical and biological criteria.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 months objective response rate</measure>
    <time_frame>6 months</time_frame>
    <description>The primary endpoint will be the 6-month objective response to treatment measured using the RECIST 1.1 scale. The objective response is defined as the aggregation of the complete + partial response against stabilization + progression.
The distribution of the objective response rate with respect to the value of individual lymphocyte DPD activity before treatment will be examined. This analysis will consist in comparing the objective response rate between patients with a proficient DPD phenotype, measured by lymphocyte DPD activity (&gt; at the 3rd quartile, ie 25% of the initial population) and non-deficient patients with DPD (including phenotype). between the 13th and 75th percentiles of the initial population).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6 months objective response in proficient DPD phenotype</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between the level of lymphocyte DPD activity and uracil dosage</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Capecitabine Toxicity using CTCAE v 5.0</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">155</enrollment>
  <condition>Breast Neoplasm Malignant Female</condition>
  <arm_group>
    <arm_group_label>DPD activity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DPD activity assessment</intervention_name>
    <description>Phenotyping DPD with enzyme activity measure and uracil dosage</description>
    <arm_group_label>DPD activity</arm_group_label>
    <other_name>Phenotyping</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine assignement at 1000mg per square meter twice daily, cycle of 21 days, 14 days of intake, 7 days of</description>
    <arm_group_label>DPD activity</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18,

          -  Performance status 0 to 2,

          -  Patients with metastatic HER2 negative breast cancer,

          -  Patients eligible for capecitabine monotherapy at a dose of 2000 mg / m² / day, 14
             days every 21 days,

          -  Determination of Uracil level performed according to national recommendations,

          -  Patients with at least one lesion evaluable according to the RECIST criteria 1.1. In
             the case of single cutaneous metastasis (s), it is required to make photographs of
             lesions with a measure of the lesions using a ruler,

          -  Patients receiving social coverage.

        Exclusion Criteria:

          -  Performance status&gt; 2,

          -  Contraindication to capecitabine monotherapy at a dose of 2000 mg / m² / day, 14 days
             every 21 days,

          -  Presence of untreated or uncontrolled symptomatic cerebral or leptomeningeal
             metastases (unstable corticosteroid requirements) and / or non-clinically stable in
             the 3 months prior to inclusion,

          -  History of cancer, with the exception of cancers in complete remission for more than 5
             years, totally resected cutaneous basal cell carcinoma, in situ carcinoma or in situ
             cervical epithelioma treated,

          -  Vulnerable people
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christine LOVERA</last_name>
    <phone>+33 492031618</phone>
    <email>christine.lovera@nice.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique Saint Jean</name>
      <address>
        <city>Cagnes-sur-Mer</city>
        <zip>06800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jérôme Barriere</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Azuréen de Cancérologie</name>
      <address>
        <city>Mougins</city>
        <zip>06250</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Remy Largilier</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique St Georges</name>
      <address>
        <city>Nice</city>
        <zip>06105</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ophélie CASSUTO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne CREISSON</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Princesse Grâce</name>
      <address>
        <city>Monaco</city>
        <zip>98000</zip>
        <country>Monaco</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georges Garnier</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Monaco</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

